SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) announced that the company will hold a conference call today to provide an update on the regulatory review of recombinant thrombin (rThrombin).
The ZymoGenetics conference call may be accessed on August 22 at 5:00 p.m. Eastern Time by dialing 877-407-0782 (International: 201-689-8567). Participants should dial in to the call approximately 10 minutes prior to the scheduled start time to register. The webcast can be accessed at http://www.zymogenetics.com (in the Investor Relations Events section). The conference call and live webcast will be archived for 30 days.
For replay, please visit http://www.zymogenetics.com or use the following information:
-- U.S. callers: 877-660-6853
-- International callers: 201-612-7415
Replay passcode account #: 286
Conference ID #: 253354
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit http://www.zymogenetics.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future actions or performance and may involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
Investor and Media Relations
Susan W. Specht, MBA
Associate Director, Corporate Communications
|SOURCE ZymoGenetics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved